Abstract
[(11)C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was to determine the 28-day test-retest repeatability (TRT) of quantitative [(11)C]UCB-J brain positron emission tomography (PET) imaging in Alzheimer's disease (AD) patients and healthy controls (HCs). Nine HCs and eight AD patients underwent two 60 min dynamic [(11)C]UCB-J PET scans with arterial sampling with an interval of 28 days. The optimal tracer kinetic model was assessed using the Akaike criteria (AIC). Micro-/macro-parameters such as tracer delivery (K(1)) and volume of distribution (V(T)) were estimated using the optimal model. Data were also analysed for simplified reference tissue model (SRTM) with centrum semi-ovale (white matter) as reference region. Based on AIC, both 1T2k_V(B) and 2T4k_V(B) described the [(11)C]UCB-J kinetics equally well. Analysis showed that whole-brain grey matter TRT for V(T), DVR and SRTM BP(ND) were -2.2% ± 8.5, 0.4% ± 12.0 and -8.0% ± 10.2, averaged over all subjects. [(11)C]UCB-J kinetics can be well described by a 1T2k_V(B) model, and a 60 min scan duration was sufficient to obtain reliable estimates for both plasma input and reference tissue models. TRT for V(T), DVR and BP(ND) was <15% (1SD) averaged over all subjects and indicates adequate quantitative repeatability of [(11)C]UCB-J PET.